行情

ABIO

ABIO

方舟生物医药
NASDAQ

实时行情|Nasdaq Last Sale

5.76
+0.02
+0.35%
交易中 10:18 09/20 EDT
开盘
5.64
昨收
5.74
最高
5.76
最低
5.51
成交量
2.14万
成交额
--
52周最高
20.45
52周最低
4.725
市值
838.40万
市盈率(TTM)
-0.8255
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ABIO 新闻

  • ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
  • GlobeNewswire.09/12 13:30
  • 71 Biggest Movers From Yesterday
  • Benzinga.09/12 09:33
  • ARCA Bio up 19% premarket ahead of presentation of Gencaro data
  • seekingalpha.09/11 18:05
  • 48 Stocks Moving In Wednesday's Mid-Day Session
  • Benzinga.09/11 16:27

更多

所属板块

制药
+1.32%
制药与医学研究
+1.19%

热门股票

名称
价格
涨跌幅

ABIO 简况

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
展开

Webull提供Arca Biopharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。